Group 1 - RAPT Therapeutics Inc. has been identified as a promising investment opportunity with significant upside potential, as indicated by Wells Fargo raising its price target from $38 to $48 while maintaining an Overweight rating [1] - The efficacy of RAPT's anti-IgE antibody therapy (RPT904) is reported to be comparable or superior to XOLAIR, particularly in the treatment of Chronic Spontaneous Urticaria, with dosing every 12 weeks [1][2] - RAPT's therapy targets multiple food allergies and is expected to perform well in the market due to its similar epitope to XOLAIR, which could lead to substantial sales even at competitive pricing [2] Group 2 - RAPT Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for oncology and inflammatory diseases, addressing unmet medical needs in the US [3]